At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDI CALIDI BIOTHERAPEUTICS INC
Market Closed 06-26 16:00:00 EDT
0.1631
+0.0133
+8.88%
盘后0.1637
+0.0006+0.37%
19:59 EDT
High0.1871Low0.1456Vol17.74M
Open0.1467D1 Closing0.1498Amplitude27.70%
Mkt Cap3.15MTradable Cap1.70MTotal Shares19.31M
T/O2.98MT/O Rate170.08%Tradable Shares10.43M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit
Reuters  ·  06-24
Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit
Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board
Reuters  ·  06-23
Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors
THOMSON REUTERS  ·  06-23
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors
Calidi Biotherapeutics shareholders approve reverse stock split authorization
Reuters  ·  06-19
Calidi Biotherapeutics shareholders approve reverse stock split authorization
Calidi receives pre-IND regulatory feedback from FDA for CLD-401
TIPRANKS  ·  06-16
Calidi receives pre-IND regulatory feedback from FDA for CLD-401
Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback
Reuters  ·  06-16
Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback
Calidi Biotherapeutics Receives Positive Pre-Ind Feedback From US FDA for Cld-401 Indicating Agreement on Its Current Development Strategy as It Advances Towards a First-in-Human Study
THOMSON REUTERS  ·  06-16
Calidi Biotherapeutics Receives Positive Pre-Ind Feedback From US FDA for Cld-401 Indicating Agreement on Its Current Development Strategy as It Advances Towards a First-in-Human Study
Calidi Biotherapeutics - Targets Cld-401 Regulatory Submission by Year-End, First-in-Human Trial in Early 2027
THOMSON REUTERS  ·  06-16
Calidi Biotherapeutics - Targets Cld-401 Regulatory Submission by Year-End, First-in-Human Trial in Early 2027
Calidi Biotherapeutics - FDA and Calidi Agree on Cmc, Non-Clinical, and Study Design for Cld-401
THOMSON REUTERS  ·  06-16
Calidi Biotherapeutics - FDA and Calidi Agree on Cmc, Non-Clinical, and Study Design for Cld-401
Calidi Biotherapeutics issues amended warrant for 17,391,304 shares at $0.23 in private placement
Reuters  ·  05-30
Calidi Biotherapeutics issues amended warrant for 17,391,304 shares at $0.23 in private placement
Calidi announces online abstract acceptances at 2026 ASCO Meeting
TIPRANKS  ·  05-26
Calidi announces online abstract acceptances at 2026 ASCO Meeting
Calidi Biotherapeutics to present RedTail platform data at ASCO annual meeting
Reuters  ·  05-26
Calidi Biotherapeutics to present RedTail platform data at ASCO annual meeting
Calidi provides required NYSE American disclosure
TIPRANKS  ·  05-23
Calidi provides required NYSE American disclosure
Calidi flags going-concern note in 2025 audit report for NYSE American disclosure
Reuters  ·  05-23
Calidi flags going-concern note in 2025 audit report for NYSE American disclosure
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate
Benzinga  ·  05-15
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate
Calidi Biotherapeutics Q1 net loss narrows 19% to $4.11 million
Reuters  ·  05-15
Calidi Biotherapeutics Q1 net loss narrows 19% to $4.11 million
Press Release: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Dow Jones  ·  05-15
Press Release: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics CSO presents RedTail platform at ASGCT conference
Reuters  ·  05-13
Calidi Biotherapeutics CSO presents RedTail platform at ASGCT conference
Calidi issues warrant for up to 17,391,304 shares at $0.23 in private placement
Reuters  ·  05-09
Calidi issues warrant for up to 17,391,304 shares at $0.23 in private placement
BRIEF-Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Reuters  ·  04-29
BRIEF-Calidi Biotherapeutics Announces Strategic Partnership With Transferai

Introduction

Company Name.
CALIDI BIOTHERAPEUTICS INC
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Issue price:
--